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Stanozolol is still the most commonly used illicit anabolic-androgenic steroid (AAS) in
professional sports. Therefore, accurate and fast analysis and long detection windows
are of great interest in the field of antidoping analysis. In this work, a very simple,
fast, and highly sensitive online solid-phase extraction method coupled with liquid
chromatography–high-resolution tandem mass spectrometry (HPLC-HRMSMS) for
the analysis of stanozolol-N-glucuronides was developed. This fully validated proce-
dure is characterized by only a few manual steps (dilution and addition of internal
standard) in the sample preparation. A limit of identification (LOI) of 75 pg/mL, high
accuracy (87.1%–102.1%), precision (3.1%–7.8%), and sensitivity was achieved. Fur-
thermore, good linearity (> 0.99) and robustness, as well as no carry-over effects,
could be observed. In addition to excellent confirmation analysis performance, this
method shows sufficient potential for the identification and characterization of
unknown metabolites. Using this method, it was possible to unambiguously confirm
the presence of 10N- and 20N-stanozolol-glucuronide in human urine for the first time
due to the access to reference material.
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1 | INTRODUCTION
Since the beginning of doping analysis, knowledge about the window
of opportunity for the detection of illicit substances has been of great
interest. The discovery of so-called long-term metabolites (LTM) of
substances listed on the Prohibited List of the World Anti-Doping
Agency (WADA),1 is still one of the most important topics in current
antidoping research.2 In particular, the analysis of anabolic-androgenic
steroids (AAS), which represent the most frequently detected class of
illicitly used substances in professional sport,3 has always been a
major priority in the field of doping analysis.2,4 Conventional steroid
analysis is based on the enzymatic cleavage of steroid phase-II metab-
olite conjugates and the following analysis of remaining parent mole-
cules and phase-I metabolites as their trimethylsilyl-derivatives with
gas chromatography-tandem mass spectrometry (GC–MS/MS).5,6
Although this very sensitive and highly efficient method is still the
gold standard for routine steroid analysis in doping control, many pre-
vious studies have shown that the direct analysis of steroid phase-II
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conjugates using liquid chromatography–tandem mass spectrometry
(LC–MS/MS), is a highly promising approach for the detection of
unknown steroid metabolites, respectively LTMs.7–15 In most cases,
phase-II metabolites are excreted in urine as glucuronide- and/or
sulfate-conjugates. Both conjugates lead to an increase in water solu-
bility, allowing urinary excretion.16–19
According to WADA statistics, stanozolol (17α-methyl-5α-
androst-2-eno[3,2-c]pyrazol-17β-ol) is the most detected substance
within the class of AAS.3 It was first synthesized in 1959 and due to
its special structure with a pyrazole ring fused to the androstane
framework, it has a unique place in the family of AAS.20 To date,
many stanozolol metabolites have been described. Donike and
Schänzer developed the detection of the metabolite 30-OH-
stanozolol as early as 1986 and successfully implemented the
method for the Olympic Games in Seoul in 1988.21 In the following
years, many papers concerning stanozolol metabolites have been
published and a high number of stanozolol metabolites have been
described.22–31 Both GC–MS/MS and LC–MS/MS methods were
developed and improved and, as a result, the limits of identification
(LOI) became lower and the detection windows for stanozolol larger.
All these above-mentioned methods use an indirect analytical
approach by detecting the remaining hydrolyzed parent molecules or
phase-I metabolites. In 2012, Van Enoo et al. developed the first
highly sensitive method for the direct detection of 30OH-stanozolol-
glucuronide by LC–MS/MS.32 Further published methods either use
a solid-phase-extraction (SPE) as sample preparation followed by LC–
MS/MS analysis or a direct, so-called dilution-and-shoot approach,
without any sample preparation, for the analysis of phase-II conju-
gates.9,14,15,33,34 The objectives of SPE are the trapping and concen-
tration of analytes and the removal of interfering substances from
biological matrices in order to improve the detection in the following
instrumental analysis. Therefore, SPE has become one of the most
important preparation techniques for the analysis of small molecules
in biological samples. However, sample preparation with SPE can be
very time and resource consuming. The present work aimed to com-
bine the advantages of SPE with a fast and simple dilute-and-shoot
method. The result is the development of a simple, fully automatic
online-SPE-LC-HRMS/MS method for the analysis of steroid-glucuro-
nides, in particular for stanozolol-glucuronides. The method validation
shows a highly sensitive and specific procedure with minimal sample
preparation effort.
Initially developed for the confirmation analysis of stanozolol-
glucuronides in routine doping control, our method shows very good
selectivity and mass accuracy, allowing us to use it for the identifica-
tion and characterization of new, unknown metabolites. In 2013,
Schänzer et al. demonstrated the utility of direct detection of
stanozolol glucuronides by high-resolution mass spectrometry
(HRMS) coupled to LC in routine doping control and they additionally
found and described two new metabolites, stanozolol-N-glucuronide
and 17-epistanozolol-N-glucuronide.33 These metabolites are resis-
tant to enzymatic hydrolysis with beta-glucuronidase and have a high
potential for long-term detection. Stanozolol and corresponding
metabolites have two feasible N-atoms (10N/20N) for the conjugation
of glucuronic acid. However, the exact position of the glucuronic acid
on the pyrazole ring was not clarified. In 2015, Thevis et al. suggested
the existence of both 10N- and 20N-stanozolol-glucuronides, based on
experiments with collision cross-section computation, but they could
not unequivocally confirm the position of the N-glucuronides.34 In this
work, with the presented method and synthesized reference stan-
dards35 we aimed to confirm unambiguously the presence of 10N- and
20N-stanozolol-glucuronide in human urine samples after administra-
tion of stanozolol.
2 | EXPERIMENTAL
2.1 | Chemicals, reagents, and solutions
Methanol (MeOH) and water used for HPLC analysis (HPLC grade)
were purchased from Biosolve Chimie (Dieuze, France). Formic acid
(FA) for HPLC was bought from Merck (Darmstadt, Germany). Water
(MQ) for sample dilution was obtained by a Milli-Q water purification
system (Millipore, Reference A+, Burlington, Massachusetts, USA).
Methanol for standard solutions was supplied by Chem-Lab
(Zedelgem, Belgium). The internal standard (IS) 16,16,17α-d3-testos-
terone-glucuronide was purchased from the National Measurement
Institute Australia (Sydney, Australia). Both 10N- and 20N-stanozolol-
glucuronide standards were synthesized and characterized by nuclear
magnetic resonance spectroscopy in a previously published study.35
The chemical structures of all substances involved are illustrated in
Figure 1. A concentration of 1 ng stanozolol-glucuronide corresponds
to approximately 0.65 ng free stanozolol.
Both the IS solution and standard stock solutions were prepared
by dissolving 1 μg of standard substance in 1 mL MeOH (1 μg/mL). A
standard working solution was made by diluting stock solutions with
MeOH. All solutions were stored at −20C. For reference samples,
the methanolic working solution was directly added to blank urine.
2.2 | Urine samples
The positive urine samples shown in this work were collected by
accredited sample collection authorities in compliance with WADA’s
collection guidelines.36 The anonymized samples were received, ana-
lyzed, and subsequently provided by the WADA accredited anti-
doping laboratory Seibersdorf Labor GmbH. Other already
characterized stanozolol metabolites had previously been confirmed
in these samples. Before the analysis, the athletes gave permission to
use the urine samples for research purposes. This is in accordance
with the International Standard for Laboratories (ISL).37 Additionally,
WADA proficiency test samples were used, which are excretion sam-
ples and sent to antidoping laboratories as part of the educational
external quality assessment scheme (EQAS). Blank urine samples
were collected from healthy female and male volunteers working at
Seibersdorf Labor GmbH. All urine samples were stored frozen at
−20C until analysis.
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2.3 | Sample preparation
For the analysis, 0.5 mL of urine was diluted with 0.5 mL MQ and
30 μL IS (final concentration: 30 ng/mL) solution was added. After-
wards, the samples were vortexed for 10 seconds.
2.4 | Online solid-phase extraction (online SPE)
The online-SPE is based on a standard UHPLC dual-pump system, in
which an additional extraction column is attached before the
analytical column via a valve system. As an extraction column, an
Accucore Phenyl-Hexyl, 10 × 3 mm column with 2.6 μm particle size
and 80 Å pore size was used (Fischer Scientific, Loughborough, UK).
As illustrated in Figure 2, the extraction column was installed
upstream to a two-position, six-port UHPLC valve (MXT715–000,
Rheodyne LLC, Bensheim, Germany). The column was connected to
the valve by installing a Universal Uniguard Holder 2.1/3.0 mm ID
(Thermo Scientific, Bellefonte, USA). For step 1 (see also Figure 2),
the sample loading and washing, the valve is set to position 1–2,
which directs the liquid stream through the extraction column and
into a waste container. This procedure traps analytes on the
F IGURE 1 Chemical structures of (A) 10N-stanozolol-glucuronide (1 N-STANG), (B) 20N-stanozolol-glucuronide (2 N-STANG), and (C) internal
standard: 16,16,17α-d3-testosterone-glucuronide (D3-TESG)
F IGURE 2 Online solid-phase
extraction procedure:
(A) Schematic illustration of the
valve switch system; above: Step
1, Loading of analytes on
extraction column and washing;
below: Step 2, Eluting analytes
from extraction column,
separating on analytical column
and HRMS measurement
(B) Temporal progression of the
experimental procedure [Colour
figure can be viewed at
wileyonlinelibrary.com]
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pre-column and flushes matrix compounds, such as proteins or salts,
into the waste. After 2 minutes the valve switches from position 1–2
to 1–6, thereby leading the stream via the analytical column to the
mass spectrometer. Simultaneously with valve switching (step 2), the
solvent gradient is started and the elution of analytes from the
extraction column begins. After finishing the separation, the system
is flushed and re-equilibrated. Connections between single
components were established with Viper Capillary finger-tight fittings
(Thermo Fisher, Austin, Texas, USA).
2.5 | Liquid chromatography – high-resolution mass
spectrometry (LC-HRMS)
Measurements were performed on a Vanquish Horizon UHPLC+ Sys-
tem coupled to a Q-Exactive Orbitrap high-resolution mass
spectrometer (Thermo Fisher, Austin, Texas, USA). As an analytical col-
umn, a Kinetex EVO C-18, 100 × 2.1 mm column with 2.6 μm particle-
and 100 Å pore size was used (Phenomenex, Aschaffenburg, Germany).
Chromatography was carried out with mobile phases containing water
with 0.2% v/v FA (solvent A) and methanol with 0.1% v/v FA (solvent
B). The separation was performed with a constant flow of 0.4 mL/min
and constant temperature at 25C. After loading and washing the pre-
column with 10% solvent B for 2 minutes, the solvent gradient con-
tinues as follows: start with 10% solvent B up to 100% over 7 minutes,
hold 100% B for 2 minutes and again 10% B for 2 minutes to flush and
re-equilibrate the system. The sample injection volumewas 25 μL.
High-resolution mass spectrometry (HRMS) was carried out in
positive electrospray ionization (ESI+) in the modes full scan and paral-
lel reaction monitoring (PRM) with the following common settings:
The spray voltage was 3.8 kV and the capillary temperature was set to
320C. Nitrogen was used as the sheath gas (pressure 25 units) as
well as auxiliary gas (pressure 8 units) and the auxiliary gas heater
temperature was set to 310C. The s-lens RF level was set to 55 and
the sweep gas flow rate was 0. The mass resolution was set to
70 000 at m/z 200 and automatic gain control (AGC) to 2 × 105 ions.
The maximum IT was set to 100 ms. Internal calibration with the lock-
mass m/z 391.2843 (di-isooctyl phthalate) was used. Full scanning
was performed in the range of m/z 300–600. PRM measurements
were carried out in separate runs. Isolation windows were set to
1 m/z. Collision energies (CE) were optimized to obtain the most
abundant signal intensities. Spectrometric parameters were optimized
by injection of the methanolic compound solutions. The chosen diag-
nostic ions and corresponding CEs are summarized in Table 1. Data
were processed and monoisotopic masses were calculated with
Thermo Xcalibur Qual Browser 4.1.45. All systems were controlled
with Xcalibur 4.0 (Thermo Fischer).
2.6 | Method validation
The method introduced in this work was validated for qualitative
and semi-quantitative purposes according to the ISL using the
parameters presented below. Samples described in the following sec-
tions were measured with the above described PRM-method. To
create extraction ion chromatograms (XIC), product ion 1 and
2 shown in Table 1 with an ion extraction range of 2 ppm were used.
For all quantitative parameters the peak area of product ion 1 was
taken. Values were corrected with the internal standard and calcu-
lated with a calibration curve, which was established for each
measurement sequence. Data processing was carried out with
Thermo Xcalibur Quan Browser 4.1.45 and calculations were
performed with Microsoft Excel 2010.
A concentration of 1 ng/mL, used for most of the parameters,
represents 50% of the minimum required performance level for free
stanozolol, defined by WADA.38 For specificity, robustness, and limit
of identification (LOI), the comparison of retention times and ratios of
relative abundances of two ion transitions must fulfil WADA
identification criteria.39
2.7 | Specificity
Five different male and five different female urine samples from
healthy volunteers were spiked with 1 ng/mL standard. Additionally,
five male and five female blank urine samples were analyzed (n = 10).
The absence of interferences for both diagnostic ions was verified.
Retention times and relative abundances of two ion transitions (peak
area) were compared.
2.7.1 | Precision
Ten replicates of urine samples were spiked with standard working
solution at three different concentrations, low 1 ng/mL, medium
10 ng/mL, and high 50 ng/mL (n = 3 × 10). Samples were measured
on 3 consecutive days and the coefficient of variation (CV) for intra-
and inter-day precision was calculated.
TABLE 1 Mass transitions applied for parallel reaction monitoring
Substance Formula Precursor ion Species Product ion 1 Product ion 2
[m/z] [m/z] / [eV] [m/z] / [eV]
1 N-STANG C27H40N2O7 505.2908 [M + H]+ 329.2587/60 81.0447/70
2 N-STANG C27H40N2O7 505.2908 [M + H]+ 329.2587/60 81.0447/70
D3-TESG C25H32D3O8 468.2671 [M + H]+ 109.0645/35 97.0651/35
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2.7.2 | Robustness
Urine samples spiked with 1 ng/mL standard working solution at vari-
ous pH values (3, 6,9) and specific gravities (0.005, 0.010, 0.015,
0.025, 0.032) were measured and different injection volumes (15 μL,
25 μL, 35 μL) were tested. Retention times and relative abundances of
two ion transitions were compared.
2.7.3 | Linearity
Four replicates of urine samples, spiked with standard working solu-
tion at six different concentrations, (1, 10, 25, 50, 75, and
100 ng/mL, n = 4 × 6), were measured and a calibration curve was
generated. Linearity (r2) was calculated with the software Thermo
Quan Browser.
2.7.4 | Accuracy
Ten replicates of urine samples, spiked with standard working
solution at three different concentrations, low 1 ng/mL, medium
10 ng/mL, and high 50 ng/mL (n = 3 × 10), were measured.
Accuracy was calculated (determined concentration/nominal
concentration*100%).
2.7.5 | Matrix effects
Six urine samples obtained from six different volunteers and one
matrix-free sample (MQ), spiked with 1 ng/mL standard working solu-
tion, were measured and average ion suppression or enhancement
effects were calculated by comparison of the signal area (normalized
with IS) of urine samples with the matrix-free samples.
2.7.6 | Carryover
A urine sample spiked with 200 ng/mL standard working solution was
measured directly prior to a blank urine specimen. The presence of
signals in the blank sample was calculated (%).
2.7.7 | Limit of identification (LOI)
Three urine samples collected from three different volunteers,
spiked with standard working solution at three concentrations
(0.025, 0.05, 0.075 ng/mL, n = 3 × 3), close to an estimated LOI,
were measured. The LOI was defined as the lowest concentration
level at which a compound could be clearly identified. Therefore,
retention times and relative abundances of two ion transitions were
compared. The term LOI, used by WADA, is to be equated to the
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2.7.8 | Identification of stanozolol-N-glucuronides
In antidoping analysis, an unequivocal identification of newly discov-
ered metabolites is extremely important. A proper way to achieve this
is a combination of chromatography, high-resolution mass spectrome-
try, and nuclear magnetic resonance spectroscopy. In this work, refer-
ence standards of 10N- and 20N-stanozolol-glucuronide were
compared with human urine samples that were confirmed to be posi-
tive for stanozolol.
3 | RESULTS AND DISCUSSION
3.1 | Method validation
The obtained method validation parameters are summarized in
Table 2. Good specificity and robustness were demonstrated in all
10 of 10 and 11 of 11 samples for both 10N- and 20N-stanozolol-
glucuronide, respectively. In all samples, no interfering signals were
observed and WADA identification criteria for ion ratios and reten-
tion time were fulfilled. The method shows excellent precision and
accuracy values. The CV for intra-day precision ranged from 3.1%
to 5.5% for both metabolites and the CV for inter-day precision
was between 3.4% and 7.8%. Accuracy varied between 87.0% and
102.1%. An improvement in the accuracy with increasing concen-
tration of the substance could be observed. A linear signal
response of both metabolites with increasing concentration in the
sample matrix was shown. No carryover could be observed after
injection of high substance concentrations. The high matrix effects
of above 150% may be explained by the lack of elaborate sample
preparation, but it does not seem to have any influence on the
precision and accuracy of the method. Rather a signal enhance-
ment was observed in all samples. Therefore for quantitative
issues, a matrix-matched calibration is needed. We could detect
both metabolites with a concentration of 25 pg/mL and S/N > 3
in all samples. However, at this concentration level, the ion ratios
did not fulfill WADA’s identification criteria. Even though in analyt-
ical chemistry S/N > 3 is often consulted for the LOI (LOD) defini-
tion, we decided to consider the stricter LOI criteria defined by
WADA. This applies to a concentration of 75 pg/mL glucuronide,
which corresponds to approximately 50 pg/mL of free stanozolol.
Most likely, an additional conventional SPE sample separation prior
to analytical measurement could significantly improve the LOI if it
is required.
F IGURE 3 Results of full-MS scan; XIC (middle, m/z 505.2908, ESI+, 2 ppm mass tolerance) and corresponding HRMS spectra (left and right)
of 1 N-STANG and 2 N-STANG in positive urine, blank urine, and reference standards
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3.2 | Identification of synthesized products
The metabolites 10N- and 20N-stanozolol-glucuronide were identified
by using mass spectrometric techniques. For definitive proof of the
existence of these two metabolites, positive doping samples for
stanozolol were compared with reference standards and blank urine
samples. The above-described method was used for the acquisition of
both full-MS scans and MS/MS measurements.
3.3 | HPLC-full-HRMS
As a first step for the identification of synthesized products, HPLC-
full-HRMS scans of positive samples for stanozolol, reference stan-
dards, and blank samples were measured. When the MS-range was
set to m/z 505.2908 (mass tolerance 2 ppm) which corresponds to
the theoretical mass of [stanozolol-mono-glucuronide + H] +, the
results showed a perfect match for both retention times and full-
HRMS spectra for both metabolites. The deviations of the retention
times were close to zero and the differences between theoretical
mass and experimental mass were below 2 ppm in all cases. No signals
at all could be observed in blank urine samples. The chromatographic
and mass-spectrometric results are shown in Figure 3.
3.4 | HPLC-HRMS/MS
As a second step for the identification of unknown metabolites,
PRM was performed on a positive stanozolol sample, reference
standards, and blank urine samples. The precursor ion was filtered
at m/z 505.2908. Fragmentation with 60 eV collision energy and a
following scan were carried out. The chromatograms, again with an
ion extraction range of 2 ppm, and resulting fragment spectra are
shown in Figure 4. Again, the deviations of the retention times
were close to zero and the differences between theoretical mass
and experimental mass were below 4 ppm for the 329 fragments
and below 6 ppm for the 81 fragments. More interferences in the
smaller mass range, as visible in Figure 4, led to a higher deviation
of the mass accuracy. All four signals show a highly similar frag-
mentation pattern, with the most abundant peak at m/z 329 and
the second most abundant peak at m/z 81. The 329 ion represents
the parent stanozolol molecule, generated after the loss of the
glucuronic acid. The 81 ion is a characteristic fragment for
stanozolol, which has previously been accurately described in the
literature.30 It represents a stable six-membered heterocyclic ring
structure formed by the pyrazole ring and an additional carbon
from the steroidal framework. Again, no signals could be observed
in blank urine samples.
F IGURE 4 Results of PRM measurements; XIC (middle; m/z 505.2908 - > 329.2587 (60 eV), ESI+, 2 ppm mass tolerance) and corresponding
PRM spectra (left and right) of 1 N-STANG and 2 N-STANG in positive urine, blank urine, and reference standards
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According to the WADA identification criteria, the ratios of at
least two MS/MS-transitions of the targeted analyte in a positive
sample and a reference sample have to be compared. Additionally,
the retention times have to match in both sample types. In
Table 3 the compared retention times, the chosen transitions with
corresponding relative abundances, and maximum tolerated values
are shown. The abundance of the transitions was determined from
the peak area. The relative abundance was calculated by dividing
the area of the less intense signal by the area of the more intense
signal (100%).
For both metabolites, the retention times in the positive
sample match with the retention times in the reference sample.
The relative difference in both cases is far below the tolerated
level of 1%. Similar good matches were achieved for the relative
abundances. In both cases, the relative difference is below 1%,
which is much lower than the accepted ±5%. These data clearly
confirm the presence of 10N- and 20N-stanozolol-glucuronide in
human urine.
4 | CONCLUSION
In the present study, we introduce a novel, highly functional analytical
method for the analysis of stanozolol-glucuronides for doping control
analysis. Sample preparation is reduced to diluting the sample with
water and adding an internal standard solution. We established a very
simple approach for installing an automatic online solid-phase extrac-
tion coupled with UHLPC-HRMS/MS. The method is characterized by
satisfactory validation parameters. The LOI of 75 pg/mL, excellent
specificity, precision, and accuracy as well as good linearity and
robustness make our method interesting for very fast and sensitive
confirmation procedures, but also for the identification and characteri-
zation of unknown metabolites. We could unambiguously identify the
presence of 10N- and 20N-stanozolol-glucuronide in human urine with
the present method. We suggest that these two metabolites can be
used as additional information for initial testing and confirmation pro-
cedures for the analysis of stanozolol in human urine. In this paper,
we focus on the analysis of N-stanozolol-glucuronides, but our
method also showed highly promising results for 3-OH-stanozolol-
glucuronides (data not shown).
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